scholarly journals Improvement in affinity and thermostability of a fully human antibody against interleukin-17A by yeast-display technology and CDR grafting

2019 ◽  
Vol 9 (5) ◽  
pp. 960-972 ◽  
Author(s):  
Wei Sun ◽  
Zhaona Yang ◽  
Heng Lin ◽  
Ming Liu ◽  
Chenxi Zhao ◽  
...  
Keyword(s):  
Human Antibody ◽  
Yeast Display ◽  
Interleukin 17A ◽  
Display Technology ◽  
Cdr Grafting

scholarly journals Yeast display platform technology to prepare oral vaccine against lethal H7N9 virus challenge in mice

2020 ◽  
Author(s):  
Han Lei ◽  
Bowen Xie ◽  
Tong Gao ◽  
Qianhong Cen ◽  
Yi Ren
Keyword(s):  
Influenza A ◽  
Oral Vaccine ◽  
H7n9 Virus ◽  
Yeast Display ◽  
Igg Antibody ◽  
Virus Challenge ◽  
Alternative Approach ◽  
New Strategy ◽  
Display Technology ◽  
Yeast Surface

Abstract Background Existing methods for preparing influenza vaccines pose the greatest challenge against highly pandemic avian influenza H7N9 outbreak in the poultry and humans. Exploring a new strategy for manufacturing and delivering a safe and effective H7N9 vaccine is needed urgently. Results An alternative approach is to develop an influenza H7N9 oral vaccine based on yeast display technology in a timely manner. Hemagglutinin (HA) of A/Anhui/1/2013 (AH-H7N9) is used as a model antigen and characterized its expression on the surface of Saccharomyces cerevisiae (S.cerevisiae) EBY 100. Mice administrated orally with S.cerevisiae EBY100/pYD5-HA produced significant titers of IgG antibody as well as significant amounts of cytokines IFN-γ and IL-4. Importantly, S.cerevisiae EBY100/pYD5-HA could provide effective immune protection against homologous A/Anhui/1/2013 (AH-H7N9) virus challenge. Conclusions Our findings suggest that platform based on yeast surface technology provides an alternative approach to prepare a promising influenza H7N9 oral vaccine candidate that can significantly shorten the preparedness period and result in effective protection against influenza A pandemic. Keywords: S.cerevisiae EBY100/pYD5-HA, Yeast display technology, Influenza A pandemic.

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

2010 ◽  
Vol 2 (52) ◽  
pp. 52ra72-52ra72 ◽  
Author(s):  
W. Hueber ◽  
D. D. Patel ◽  
T. Dryja ◽  
A. M. Wright ◽  
I. Koroleva ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Human Antibody ◽  
Interleukin 17A

626 Improving the yeast transformation efficiency for yeast display in antibody development

2020 ◽  
Vol 8 (Suppl 3) ◽  
pp. A662-A662
Author(s):  
Jian Chen ◽  
George Sun
Keyword(s):  
Development Process ◽  
Transformation Efficiency ◽  
Scaling Up ◽  
Affinity Maturation ◽  
Yeast Transformation ◽  
Yeast Display ◽  
Library Size ◽  
New Device ◽  
Display Technology ◽  
Single Reaction

BackgroundIn the therapeutic antibody development process, the yeast display technology which expresses a large library of antibodies is very useful for increasing the affinity of a lead antibody. Ideally, a yeast library should exceed the size of 10E10 to 10E11 to get close to the real affinity maturation process. However, due to low transformation efficiency with yeast, it requires trememdous scaling-up efforts to simply reach the 10E9 library size.MethodsTo address the transformation problem, we developed a new electroporation device that applies a high voltage on a sealed electroporation tube containing the yeast and plasmids in a low conductance buffer.ResultsThe new device is arcing free due to the sealed design and each single reaction could generate 10E8 library size, far exceeding the 10E6 size that was previously reported in a single reaction.ConclusionsWith the improved transformation efficiency, it becomes very straightforward to reach the currently difficult size of 10E9. Further more, it is possible to reach the 10E10 to 10E11 library size with reaction scaling-up. Our new method could be very useful for the field of antibody development.

scholarly journals Optimization of anti-ADAMTS13 antibodies for the treatment of ADAMTS13-related bleeding disorder in patients receiving circulatory assist device support

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Toshihiro Ito ◽  
Takeharu Minamitani ◽  
Masaki Hayakawa ◽  
Ryota Otsubo ◽  
Hiroki Akiba ◽  
...  
Keyword(s):  
Binding Affinity ◽  
In Silico ◽  
Structural Similarity ◽  
Bleeding Disorder ◽  
Treatment Modalities ◽  
Human Antibody ◽  
Assist Device ◽  
Life Threatening ◽  
Cdr Grafting

AbstractADAMTS13 (a disintegrin-like and metalloproteinase with thrombospondin type-1 motif 13)-related bleeding disorder has been frequently observed as a life-threatening clinical complication in patients carrying a circulatory assist device. Currently, treatment modalities for the bleeding disorder are very limited and not always successful. To address the unmet medical need, we constructed humanized antibodies of mouse anti-ADAMTS13 antibody A10 (mA10) by using complementarity-determining region (CDR) grafting techniques with human antibody frameworks, 8A7 and 16E8. The characteristics of the two humanized A10 antibodies, namely A10/8A7 and A10/16E8, were assessed in vitro and in silico. Among the two humanized A10 antibodies, the binding affinity of A10/16E8 to ADAMTS13 was comparable to that of mA10 and human-mouse chimeric A10. In addition, A10/16E8 largely inhibited the ADAMTS13 activity in vitro. The results indicated that A10/16E8 retained the binding affinity and inhibitory activity of mA10. To compare the antibody structures, we performed antibody structure modeling and structural similarity analysis in silico. As a result, A10/16E8 showed higher structural similarity to mA10, compared with A10/8A7, suggesting that A10/16E8 retains a native structure of mA10 as well as its antigen binding affinity and activity. A10/16E8 has great potential as a therapeutic agent for ADAMTS13-related bleeding disorder.

scholarly journals Ribosome display: a potent display technology used for selecting and evolving specific binders with desired properties

2018 ◽  
Author(s):  
Ruowei Li ◽  
Guangbo Kang ◽  
Min Hu ◽  
He Huang
Keyword(s):  
High Performance ◽  
Life Science ◽  
Yeast Display ◽  
Ribosome Display ◽  
Science Field ◽  
Display Technology ◽  
Selection For ◽  
Display Systems ◽  
Development Prospects

Currently, a variety of display technologies have been developed in the life science field, such as phage display, ribosome display, and yeast display. Many studies have found that display technologies are powerful and universal methods when they are combined with large genetically encoded binder libraries, which results in the generation of high-performance binders against nearly any antigen interested. As a result, display technologies are widely applied to molecular biology, clinic and medicine. Ribosome display based on cell-free display systems has been established as a different type of technology for 23 years until now. Compared to other related methods, ribosome display possesses unique advantages and is successfully exploited to the selection for functional and specific binders in vitro, exhibiting potent development prospects. Here in this paper, we will review the theories and advantages of ribosome display, and will highlight how it is being used now to select and evolve functional proteins as well as applications in diagnostics and therapeutics.

Sign in / Sign up

Export Citation Format

Share Document